Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
218.1 USD | +18.89% | +21.92% | +26.76% |
Apr. 26 | Sector Update: Health Care Stocks Edge Higher Late Afternoon | MT |
Apr. 26 | Top Midday Gainers | MT |
Summary
- The company has strong fundamentals. More than 70% of companies have a lower mix of growth, profitability, debt and visibility.
- The company's Refinitiv ESG score, based on a ranking of the company relative to its industry, comes out particularly well.
Strengths
- The company's EBITDA/Sales ratio is relatively high and results in high margins before depreciation, amortization and taxes.
- Margins returned by the company are among the highest on the stock exchange list. Its core activity clears big profits.
- The company is in a robust financial situation considering its net cash and margin position.
- There is high visibility into the group's activities for the coming years. Outlooks on future revenues from analysts covering the equity remain similar. Such hardly dispersed estimates support highly predictable sales for the current and upcoming fiscal years.
- The group usually releases upbeat results with huge surprise rates.
Weaknesses
- The company's valuation in terms of earnings multiples is rather high. Indeed, the firm is getting paid 31.43 times its estimated earnings per share for the ongoing year.
- The company's "enterprise value to sales" ratio is among the highest in the world.
- The company appears highly valued given the size of its balance sheet.
- The company is highly valued given the cash flows generated by its activity.
- The firm pays small or no dividend to shareholders. For that reason, it is not a yield company.
Ratings chart - Surperformance
Chart ESG Refinitiv
Sector: Advanced Medical Equipment & Technology
1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
---|---|---|---|---|
+26.76% | 32.03B | B+ | ||
+8.07% | 219B | B | ||
+6.59% | 183B | B- | ||
+11.26% | 133B | B- | ||
+26.57% | 108B | A- | ||
+13.35% | 52.02B | B+ | ||
-0.62% | 48.2B | B+ | ||
-0.93% | 40.37B | A | ||
+11.54% | 39.35B | - | ||
-12.18% | 19.47B | C+ |
Financials
Valuation
Momentum
Consensus
Business Predictability
Environment
Governance
Controversy
Technical analysis
- Stock Market
- Equities
- RMD Stock
- Ratings ResMed, Inc.